Aflibercept Biosimilar (Alteogen)

阿柏西普生物类似药（Alteogen）

Report date: 2026/05/21 20:00:22

Base Information

Drug NameAflibercept Biosimilar (Alteogen)
Drug Alias NameEylea Biosimilar (Alteogen)阿柏西普生物仿制药（Alteogen）ALT-L9
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitors
TargetsPlacental Growth FactorVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaChoroidal NeovascularizationRetinal Vein Occlusion +[6] 
Global Approved IndicationsDiabetic macular oedemaChoroidal NeovascularizationRetinal Vein Occlusion +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2025/09/15
Country/TerritorySouth KoreaEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAlteogen IncKissei Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiolitec Pharma LtdAlteogen Inc +[3] 
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaChoroidal NeovascularizationRetinal Vein Occlusion +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XX44S01LA05
Related LinksN/A